Locoregional Therapy plus First-Line Systemic Therapy in Unresectable Locally Advanced Intrahepatic Cholangiocarcinoma
Abstract Background and purpose Whether locoregional consolidation therapy (LCT) adds benefit to first-line systemic therapy in unresectable, locally advanced intrahepatic cholangiocarcinoma (ICC) is unknown. Methods In this single-centre retrospective cohort (2017–2025), 156 patients receiving gemcitabine-based chemotherapy plus a PD-1/PD-L1 inhibitor, with or without a tyrosine kinase inhibitor, were grouped by concomitant LCT (n = 61; radiotherapy 34, non-radiotherapy 27) or systemic therapy alone (n = 95). Stabilised inverse probability of treatment weighting (sIPTW) balanced 13 covariates; weighted Cox models and sensitivity analyses were used. Results At a median follow-up of 37.0 months, after stabilised inverse probability of treatment weighting, LCT was associated with longer progression-free survival (PFS; 17.35 vs 8.67 months; hazard ratio 0.43, 95% confidence interval 0.29–0.62; P < 0.001) and overall survival (OS; 28.91 vs 20.60 months; HR 0.59, 95% CI 0.39–0.91; P = 0.017). Across analytic approaches, hazard ratios were 0.41–0.55 for PFS and 0.49–0.71 for OS. E-values were 3.00 (PFS) and 2.23 (OS). Growth of existing intrahepatic lesions as the first progression was less frequent after radiotherapy-based consolidation (11.8% vs 41.1%; P = 0.002) but not after non-radiotherapy LCT (48.1% vs 41.1%; P = 0.52). Grade ≥ 3 lymphopenia (63.9% vs 33.7%), any-grade thrombocytopenia (82.0% vs 62.1%) and any-grade gastrointestinal ulceration (14.8% vs 2.1%) were more frequent with LCT, the ulcer excess being confined to radiotherapy-based consolidation (20.6% vs 2.1%; P = 0.001). Conclusion In unresectable ICC treated with first-line systemic therapy, consolidative LCT, and radiotherapy-based consolidation in particular, was associated with longer PFS and OS and fewer intrahepatic failures. Randomised confirmation is required.
Authors
- Jiaoyang Yang
- Huanliang Chen
- Guo‐Ming Shi (ORCID: https://orcid.org/0000-0003-3446-7875)
- Yanyan Lin
- Pan Zhou
- Xiaojun Zhang
- Kehao Liu
- QIANQIAN ZHAO
- Zhao-chong Zeng
- Jian Zhou
Institutions
- Zhongshan Hospital (CN)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-12
- DOI
- https://doi.org/10.21203/rs.3.rs-11512602/v1
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- preprint
Funders
- National Natural Science Foundation of China
- Fudan University
- National Key Research and Development Program of China